Valuation: Lexeo Therapeutics, Inc.

Market Cap 324M 282M 262M 241M 455M 30.96B 462M 3.09B 1.21B 15.41B 1.22B 1.19B 51.68B P/E 2026 *
-3.52x
P/E 2027 * -3.09x
Enterprise Value 181M 158M 147M 135M 254M 17.31B 258M 1.73B 679M 8.62B 681M 666M 28.89B EV / Sales 2026 *
-
EV / Sales 2027 * 8.93x
Free-Float
99.39%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lexeo Therapeutics, Inc.

1 day-5.06%
1 week-11.37%
1 month-11.28%
3 months-27.48%
6 months-44.26%
Current year-58.41%
1 week 4.07
Extreme 4.07
4.84
1 month 4.07
Extreme 4.07
5.38
Current year 4.03
Extreme 4.03
10.75
1 year 4.03
Extreme 4.03
10.99
3 years 1.45
Extreme 1.45
22.33
5 years 1.45
Extreme 1.45
22.33
10 years 1.45
Extreme 1.45
22.33
Manager TitleAgeSince
Chief Executive Officer 46 2019-12-31
Director of Finance/CFO 50 2025-08-14
Chief Tech/Sci/R&D Officer 62 2026-01-19
Director TitleAgeSince
Director/Board Member 46 2019-12-31
Chairman 72 2020-12-31
Director/Board Member 61 2020-10-31
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Chief Technology Officer

-22,306 0.0284%
7/1/26 Sell

Chief Operating Officer

-4,666 0.0059%
7/1/26 Sell

Chief Financial Officer

-4,641 0.0059%
Change 5-day change 1-year change 3-year change Capi.($)
-5.06%-11.37%-12.68% - 324M
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -0.62%-4.55%+29.76%+157.35% 23.42B
Weighted average by Cap. +0.22%-2.97%+28.61%+119.98%

Financials

2026 *2027 *
Net sales - 6.11M 5.31M 4.94M 4.54M 8.57M 583M 8.71M 58.29M 22.88M 290M 22.95M 22.45M 974M
Net income -97.88M -85.09M -79.2M -72.71M -137M -9.34B -139M -934M -366M -4.65B -368M -360M -15.6B -123M -107M -99.63M -91.47M -173M -11.75B -175M -1.17B -461M -5.85B -462M -452M -19.62B
Net Debt -143M -124M -116M -106M -201M -13.65B -204M -1.36B -535M -6.8B -537M -525M -22.79B -270M -234M -218M -200M -378M -25.75B -384M -2.57B -1.01B -12.82B -1.01B -991M -42.98B
Logo Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Employees
59
Date Price Change Volume
26-07-31 US$4.130 -5.06% 713,569
26-07-30 US$4.350 +0.93% 644,633
26-07-29 US$4.310 -1.82% 848,690
26-07-28 US$4.390 -1.79% 586,103
26-07-27 US$4.470 -4.08% 965,599
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.130USD
Average target price
20.89USD
Spread / Average Target
+405.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXEO Stock